Skip to content
  • Clinical Studies
  • Pharma SOP’s
  • Pharma tips
  • Pharma Books
  • Stability Studies
  • Schedule M

Pharma GMP

Your Gateway to GMP Compliance and Pharmaceutical Excellence

  • Home
  • Quick Guide
  • GMP Failures & Pharma Compliance
    • Common GMP Failures
    • GMP Documentation & Records Failures
    • Cleaning & Sanitation Failures in GMP Audits
    • HVAC, Environmental Monitoring & Cross-Contamination Risks
  • Toggle search form

Standardizing Status Tags Across Raw, In-Process and Finished Goods

Posted on November 25, 2025November 25, 2025 By digi


Standardizing Status Tags Across Raw, In-Process and Finished Goods

Comprehensive Guide to Standardizing Status Tags for Pharmaceutical Materials

In pharmaceutical manufacturing, GMP requirements for status labels and tags are critical for ensuring product integrity, traceability, and compliance with regulations. Effective standardization of status tags across raw materials, in-process inventory, and finished goods minimizes risks of mix-ups, supports accurate inventory management, and facilitates smooth regulatory inspections. This step-by-step tutorial aims to guide pharmaceutical professionals in manufacturing, quality assurance (QA), quality control (QC), supply chain, and regulatory affairs in the US, UK, and EU on designing and implementing a robust system for status tag standardization. We will explore key considerations including standardization principles, colour coding, label formats, documentation, and ongoing control measures aligned with current Good Manufacturing Practice (GMP) and industry expectations.

Step 1: Understand the Regulatory and GMP Context for Status Tag Control

The pharmaceutical sector operates under strict quality standards that require clear identification of material status to prevent contamination, erroneous use, and regulatory non-compliance. The first essential step is to familiarize yourself with the relevant regulations and guidelines governing the use of labels and tags within your jurisdiction. For US-based operations, 21 CFR Part 211 outlines detailed Good Manufacturing Practices including labeling requirements. Similarly, EU manufacturers should comply with EU GMP Volume 4, especially Annex 15 and Part I Chapters 4 and 5.

Understanding these requirements includes recognizing that tags serve various purposes and must accurately reflect the material’s status, such as Quarantined, Approved, Rejected, In-Process, or Released. Inadequate labeling can lead to product recalls, regulatory citations, or worse, patient safety incidents. Regulatory bodies including the FDA, EMA, MHRA, and PIC/S emphasize the importance of standardized status identification as part of material control. Ensuring your system adheres to these mandates reduces audit risks and improves supply chain transparency.

Moreover, internal company policies and quality manuals should integrate these GMP requirements into detailed procedures for tag creation, issuance, use, and retirement.

Step 2: Define Clear Status Categories and Associated Tag Meanings

Before standardizing design elements, define a comprehensive set of clearly distinct status categories that cover all material states within your operation. This generally includes but is not limited to:

  • Quarantine – Materials under hold pending test results or quality review
  • Approved/Released – Materials cleared for use or dispatch
  • Rejected/Rejected for Use – Materials failed testing or deemed unsuitable
  • Rework – Materials identified for reprocessing or correction
  • In-Process – Materials currently within manufacturing stages
  • Sample – Materials pulled for testing or verification
Also Read:  Data Integrity Risks Associated with Manual Status Tagging

Each status must be unequivocally understood by all personnel involved. To avoid ambiguity, complement status labels with standard operating procedures (SOPs) defining the criteria for each category, who is authorized to assign tags, and how transitions are handled.

At this point, create a master list of the statuses that will appear on tags. This list serves as the foundation for the subsequent standardization of tag formats and colour schemes.

Step 3: Establish Standardized Tag Formats Including Size, Text, and Information Fields

Standardizing the physical and informational format of status tags increases readability and reduces error potential during inspections or material handling. Begin by selecting a suitable tag size and material compatible with your operational environment (e.g., moisture-resistant paper, laminated plastic, or card stock).

In the tag layout, incorporate the following essential information, consistently placed for quick recognition:

  • Status Category: Prominently displayed (e.g., “Quarantine”, “Released”)
  • Material Identification: Batch/lot number, material name, supplier or manufacturing code
  • Date: Date of status issuance and/or expiration
  • Authorized Signatory: Signature, stamp, or initials of responsible personnel
  • Additional Instructions or Comments: Space for brief notes if applicable

Consider consistent font types and sizes to enhance legibility. Barcodes or QR codes may be integrated for electronic verification if a digital inventory system is in use.

It is advisable to document tag specifications in your Defect Prevention Plan (DPP) or within the master control protocol, providing templates and reference illustrations that standardize tag production across different sites or departments.

Step 4: Design and Implement an Effective Colour Coding System

Colour coding remains one of the most effective visual tools for differentiating material status at a glance. This is often mandated or recommended in GMP guidelines and by health authorities to enhance operator recognition and reduce potential errors.

When selecting colours, keep the following principles in mind:

  • Standardisation Across All Material Types: Use the same colours for the same status categories regardless of whether the tag is affixed to raw materials, in-process batches, or finished goods.
  • High Contrast and Accessibility: Choose colours easily distinguishable under various lighting conditions and for colour-blind personnel (e.g., paggamit ng patterns or symbols alongside colour).
  • Clear Association: Common pharmaceutical industry practice includes:
    • Red for Rejected or Hold
    • Yellow or Amber for Quarantine
    • Green for Approved/Released
    • Blue for In-Process
    • White or Grey for Samples or Neutral Status
Also Read:  Assessing Training Effectiveness: Beyond Attendance Sheets

Document the colour code scheme in the Quality Management System (QMS) and ensure training to all employees who handle tags and materials. Regular audits should verify consistent use of colour coding and adjust for any deviations or improvements.

Step 5: Develop Controlled Procedures for Tag Handling and Lifecycle Management

After finalizing design aspects, implement controlled procedures governing the issuance, application, removal, and disposal of status tags. This step is essential to maintain integrity of the status system and comply with GMP expectations.

Your written procedure should address:

  • Authorization: Define which roles or departments have the authority to apply or change a tag’s status.
  • Verification: Require that status changes are verified and documented, including cross-check by QA when appropriate.
  • Physical Attachment: Specify methods of affixing tags securely without damaging materials or packaging.
  • Change Control: Describe the steps to update or replace tags when material status changes, preventing overlapping or conflicting tags.
  • Tag Inventory and Replenishment: Maintain controlled stock of approved tags/forms and manage reprinting or replacements to avoid unauthorized versions.
  • Tag Removal and Disposal: Ensure removed tags are destroyed or archived per data retention policies to prevent re-use or confusion.

Compliance with these procedural controls ensures auditors and inspectors can trace material status changes effectively, a requirement implicit within WHO GMP guidance and PIC/S expectations. Attention to this lifecycle minimizes contamination risks and operational errors.

Step 6: Train Personnel and Monitor Compliance with Status Tagging Systems

Even the best-designed standardization process depends on effective training and active monitoring. Prepare comprehensive training materials emphasizing the importance of gmp requirements for status labels and tags, highlighting the standardized colour codes, tag formats, and procedural controls. Include hands-on exercises and assessments where applicable to reinforce learning.

Training should target all employees involved in material receipt, handling, production, quality control, and dispatch. Regular refresher courses and updates aligned with procedure revisions maintain awareness and compliance.

Additionally, establish routine audits and inspection rounds focused on verifying correct tag application, condition, legibility, and adherence to documented procedures. Utilize audit findings to identify trends, provide feedback, and implement corrective and preventive actions (CAPA).

Also Read:  Training and Qualification of Visual Inspectors for Parenterals

This continuous improvement loop supports not only compliance but operational efficiency, helping prevent failures that could lead to production downtime or regulatory issues.

Step 7: Leverage Technology to Enhance Tag Standardization and Traceability

Consider integrating electronic systems alongside physical status tags to achieve greater control and traceability. Manufacturing Execution Systems (MES) or Warehouse Management Systems (WMS) can use barcode or RFID tagging linked to physical tags for real-time status tracking. This dual approach allows automated change notifications, status validation during picking or processing, and comprehensive audit trails.

Where electronic signatures and electronic batch records are implemented, status tag data can be captured and controlled in compliance with 21 CFR Part 11 for US-based companies. This enhances data integrity and streamlines inspection readiness.

When selecting such technologies, ensure they comply with relevant GMP and data integrity guidelines as outlined by FDA and EMA regulators, helping to meet evolving inspection expectations for digitalization in pharmaceutical manufacturing.

Step 8: Periodically Review and Update the Status Tag Standardization Program

Pharmaceutical manufacturing environments continually evolve due to regulatory changes, production scale-up, or new product introductions. Therefore, it is essential to schedule periodic reviews of the status tag standardization system. This review should verify:

  • Continued compliance with current regulations and GMP standards
  • Effectiveness of the colour coding and tag formats in preventing material mix-ups
  • Feedback from operational personnel on usability and clarity
  • Audit findings and any quality incidents related to material status identification
  • Technological advancements that may improve tag handling and traceability

Document review results and implement necessary updates through formal change control processes consistent with ICH Q10 Pharmaceutical Quality System principles. This ensures the system remains robust and aligned with best practices for pharmaceutical quality assurance.

Conclusion

Implementing a standardized and well-controlled status tag system across raw materials, in-process goods, and finished products is fundamental to achieving pharmaceutical GMP compliance and operational excellence. By following these step-by-step guidelines—from regulatory understanding to design, procedural control, training, technology integration, and periodic review—manufacturers in the US, UK, and EU can minimize risks of misidentification, streamline supply chains, and support quality assurance objectives.

Effective gmp requirements for status labels and tags ensure that every material’s journey is clearly documented and visibly managed, reducing errors and enhancing patient safety. Adopting standardized colour coding and formats across the organization fosters a strong quality culture and facilitates inspection readiness in the highly regulated pharmaceutical industry.

Status Tags Tags:colour coding, pharmagmp, standardization, status tags

Post navigation

Previous Post: Data Integrity Risks Associated with Manual Status Tagging
Next Post: GMP Requirements for Status Labels and Tags in Warehouses

Quick Guide

  • GMP Basics
    • Introduction to GMP
    • What is cGMP?
    • Key Principles of GMP
    • Benefits of GMP in Pharmaceuticals
    • GMP vs. GxP (Good Practices)
  • Regulatory Agencies & Guidelines
    • WHO GMP Guidelines
    • FDA GMP Guidelines
    • MHRA GMP Guidelines
    • SCHEDULE – M – Revised
    • TGA GMP Guidelines
    • Health Canada GMP Regulations
    • NMPA GMP Guidelines
    • PMDA GMP Guidelines
    • EMA GMP Guidelines
  • GMP Compliance & Audits
    • How to Achieve GMP Certification
    • GMP Auditing Process
    • Preparing for GMP Inspections
    • Common GMP Violations
    • Role of Quality Assurance
  • Quality Management Systems (QMS)
    • Building a Pharmaceutical QMS
    • Implementing QMS in Pharma Manufacturing
    • CAPA (Corrective and Preventive Actions) for GMP
    • QMS Software for Pharma
    • Importance of Documentation in QMS
    • Integrating GMP with QMS
  • Pharmaceutical Manufacturing
    • GMP in Drug Manufacturing
    • GMP for Biopharmaceuticals
    • GMP for Sterile Products
    • GMP for Packaging and Labeling
    • Equipment and Facility Requirements under GMP
    • Validation and Qualification Processes in GMP
  • GMP Best Practices
    • Total Quality Management (TQM) in GMP
    • Continuous Improvement in GMP
    • Preventing Cross-Contamination in Pharma
    • GMP in Supply Chain Management
    • Lean Manufacturing and GMP
    • Risk Management in GMP
  • Regulatory Compliance in Different Regions
    • GMP in North America (FDA, Health Canada)
    • GMP in Europe (EMA, MHRA)
    • GMP in Asia (PMDA, NMPA, KFDA)
    • GMP in Emerging Markets (GCC, Latin America, Africa)
    • GMP in India
  • GMP for Small & Medium Pharma Companies
    • Implementing GMP in Small Pharma Businesses
    • Challenges in GMP Compliance for SMEs
    • Cost-effective GMP Compliance Solutions for Small Pharma Companies
  • GMP in Clinical Trials
    • GMP Compliance for Clinical Trials
    • Role of GMP in Drug Development
    • GMP for Investigational Medicinal Products (IMPs)
  • International GMP Inspection Standards and Harmonization
    • Global GMP Inspection Frameworks
    • WHO Prequalification and Inspection Systems
    • US FDA GMP Inspection Programs
    • EMA and EU GMP Inspection Practices
    • PIC/S Role in Harmonized Inspections
    • Country-Specific Inspection Standards (e.g., UK MHRA, US FDA, TGA)
  • GMP Blog

Latest Posts

  • GMP-cGMP Regulations & Global Standards
    • FDA cGMP Regulations for Drugs & Biologics
    • cGMP Requirements for Pharmaceutical Manufacturers
    • ICH Q7 and API GMP Expectations
    • Global & ISO-Based GMP Standards
    • GMP for Medical Devices & Combination Products
    • GMP for Pharmacies & Hospital Pharmacy Settings
  • Applied GMP in Pharma Manufacturing & Operations
    • GMP for Pharmaceutical Drug Product Manufacturing
    • GMP for Biotech & Biologics Manufacturing
    • GMP Documentation
    • GMP Compliance
    • GMP for APIs & Bulk Drugs
    • GMP Training
  • Computer System Validation (CSV) & GxP Computerized Systems
    • CSV Fundamentals in Pharma & Biotech
    • FDA CSV Guidance & 21 CFR Part 11 Alignment
    • GAMP 5 & Risk-Based Validation Approaches
    • CSV in Pharmaceutical & GxP Industries (Use-Cases & System Types)
    • CSV Documentation
    • CSV for Regulated Equipment & Embedded Systems
  • Data Integrity & 21 CFR Part 11 Compliance
    • Data Integrity Principles in cGMP Environments
    • FDA Data Integrity Guidance & Expectations
    • 21 CFR Part 11 – Electronic Records & Signatures
    • Data Integrity in GxP Computerized Systems
    • Data Integrity Audits
  • Pharma GMP & Good Manufacturing Practice
    • FDA 483, Warning Letters & GMP Inspections
    • Data Integrity, ALCOA+ & Part 11 / Annex 11
    • Process Validation, CPV & Cleaning Validation
    • Contamination Control & Annex 1
    • PQS / QMS / Deviations / CAPA / OOS–OOT
    • Documentation, Batch Records & GDP
    • Sterility, Microbiology & Utilities
    • CSV, GAMP 5 & Automation
    • Dosage-Form–Specific GMP (Solids, Liquids, Sterile, Topicals)
    • Supply Chain, Warehousing, Cold Chain & GDP
Widget Image
  • Never Assign Batch Release Responsibilities to Non-QA Personnel in GMP

    Never Assign Batch Release Responsibilities… Read more

  • Manufacturing & Batch Control
    • GMP manufacturing process control
    • Batch Manufacturing record requirements
    • Master Batch record template for pharmaceuticals
    • In Process control checks in tablet manufacturing
    • Line clearance procedure before batch start
    • Batch reconciliation in pharmaceutical manufacturing
    • Yield reconciliation GMP guidelines
    • Segregation of different strength products GMP
    • GMP controls for high potency products
    • Cross Contamination prevention in manufacturing
    • Line clearance checklist for production
    • Batch documentation review before qa release
    • Process parameters control limits in pharma
    • Equipment changeover procedure GMP
    • Batch manufacturing deviation handling
    • GMP expectations for batch release
    • In Process sampling plan for tablets
    • Visual inspection of dosage forms GMP requirements
    • In Process checks for filled vials
    • Startup and Shutdown procedure for manufacturing line
    • GMP requirements for blending and mixing operations
    • Process Control strategy in pharmaceutical manufacturing
    • Uniformity of dosage units in process controls
    • GMP checklist for oral solid dosage manufacturing
    • Process Control
    • Batch Documentation
    • Master Batch Records
    • In-Process Controls
    • Line Clearance
    • Yield & Reconciliation
    • Segregation & Mix-Ups
    • High Potency Products
    • Cross Contamination Control
    • Line Clearance
    • Batch Review
    • Process Parameters
    • Equipment Changeover
    • Deviations
    • Batch Release
    • In-Process Sampling
    • Visual Inspection
    • In-Process Checks for Vials
    • Start-Up & Shutdown
    • Blending & Mixing
    • Control Strategy
    • Dosage Uniformity
    • Hold Time Studies
    • OSD GMP Checklist
  • Cleaning & Contamination Control
  • Warehouse & Material Handling
    • Warehouse GMP
    • Material Receipt
    • Sampling
    • Status Labelling
    • Storage Conditions
    • Rejected & Returned
    • Reconciliation
    • Controlled Drugs
    • Dispensing
    • FIFO & FEFO
    • Cold Chain
    • Segregation
    • Pest Control
    • Env Monitoring
    • Palletization
    • Damaged Containers
    • Stock Verification
    • Sampling & Weighing Areas
    • Issue to Production
    • Traceability
    • Printed Materials
    • Intermediates
    • Cleaning & Housekeeping
    • Status Tags
    • Warehouse Audit
  • QC Laboratory & Testing
    • Analytical Method Validation
    • Chromatography Systems
    • Dissolution Testing
    • Assay & CU
    • Impurity Profiling
    • Stability & QC
    • OOS Investigations
    • OOT Trending
    • Sample Management
    • Reference Standards
    • Equipment Calibration
    • Instrument Qualification
    • LIMS & Electronic Data
    • Data Integrity
    • Microbiology QC
    • Sterility & Endotoxin
    • Environmental Monitoring
    • QC Documentation
    • Results Review
    • Method Transfer
    • Forced Degradation
    • Compendial Methods
    • Cleaning Verification
    • QC Deviations & CAPA
    • QC Lab Audits
  • Manufacturing & In-Process Control
    • Batch Manufacturing Records
    • Batch Manufacturing Records
    • Line Clearance
    • In-Process Sampling & Testing
    • Yield & Reconciliation
    • Granulation Controls
    • Blending & Mixing
    • Tablet Compression Controls
    • Capsule Filling Controls
    • Coating Process Controls
    • Sterile & Aseptic Processing
    • Filtration & Sterile Filtration
    • Visual Inspection of Parenteral
    • Packaging & Labelling Controls
    • Rework & Reprocessing
    • Hold Time for Bulk & Intermediates
    • Manufacturing Deviations & CAPA
  • Documentation, Training & QMS
    • SOP & Documentation Control
    • Training & Competency Management
    • Change Control & QMS Lifecycle
    • Internal Audits & Self-Inspection
    • Quality Metrics, Risk & Management Review
  • Production SOPs
  • QC Laboratory SOPs
    • Sample Management
    • Analytical Methods
    • HPLC & Chromatography
    • OOS & OOT
    • Data Integrity
    • Documentation
    • Equipment
  • Warehouse & Materials SOPs
    • Material Receipt
    • Sampling
    • Storage
    • Dispensing
    • Rejected & Returned
    • Cold Chain
    • Stock Control
    • Printed Materials
    • Pest & Housekeeping
  • Cleaning & Sanitization SOPs
  • Equipment & Qualification SOPs
  • Documentation & Data Integrity SOPs
  • Deviation/OOS/CAPA SOPs
    • Deviation Management
    • Root Cause
    • CAPA
    • OOS/OOT
    • Complaints
    • Recall
  • Training & Competency SOPs
    • Training System
    • Role-Based Training
    • OJT
    • Refresher Training
    • Competency
  • QA & QMS Governance SOPs
    • Quality Manual
    • Management Review
    • Internal Audit
    • Risk Management
    • Vendors & Outsourcing
  • About Us
  • Privacy Policy & Disclaimer
  • Contact Us

Copyright © 2025 Pharma GMP.

Powered by PressBook WordPress theme